Scott Waldman

Summary

Affiliation: Thomas Jefferson University
Country: USA

Publications

  1. pmc Molecular staging of node negative patients with colorectal cancer
    Terry Hyslop
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    J Cancer 4:193-9. 2013
  2. pmc GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity
    Jieru Egeria Lin
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 7:e31686. 2012
  3. doi Transitioning biomarkers into the clinic
    Scott A Waldman
    Thomas Jefferson University, 132 South 10th Street, Philadelphia, PA 19107, USA
    Expert Rev Clin Pharmacol 2:9-13. 2009
  4. pmc The transcription factor encyclopedia
    Dimas Yusuf
    Department of Medical Genetics, Faculty of Medicine, Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, Canada
    Genome Biol 13:R24. 2012
  5. pmc Selection of optimal reference genes for normalization in quantitative RT-PCR
    Inna Chervoneva
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
    BMC Bioinformatics 11:253. 2010
  6. ncbi Clinical pharmacology: a paradigm for individualized medicine
    Scott A Waldman
    Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA
    Biomark Med 3:679-84. 2009
  7. doi MicroRNA signatures as diagnostic and therapeutic targets
    Scott A Waldman
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA
    Clin Chem 54:943-4. 2008
  8. pmc A study of microRNAs in silico and in vivo: diagnostic and therapeutic applications in cancer
    Scott A Waldman
    Department of Pharmacology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    FEBS J 276:2157-64. 2009
  9. pmc Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer
    Scott A Waldman
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 S 10th St, Philadelphia, PA 19107, USA
    JAMA 301:745-52. 2009
  10. ncbi Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells
    Scott A Waldman
    Thomas Jefferson University, Jefferson Medical College, Department of Pharmacology and Experimental Therapeutics, Philadelphia, PA 19107, USA
    Future Oncol 2:705-16. 2006

Research Grants

Collaborators

  • Giovanni M Pitari
  • Stephanie Schulz
  • Yanyan Li
  • Inna Chervoneva
  • PAOLO M FORTINA
  • Lan Huang
  • SATISH C RATTAN
  • Andre Terzic
  • Peng Li
  • David S Weinberg
  • Henry R Wolfe
  • ERIC contact WICKSTROM
  • T Jin
  • Raymond Regan
  • Alex Mejia
  • Mathew Thakur
  • Glen S Frick
  • Adam E Snook
  • Shiva Kazerounian
  • Terry Hyslop
  • Li Gong
  • Philip R Debruyne
  • Laurence C Eisenlohr
  • Wilhelm J Lubbe
  • Ruth Birbe
  • Jieru E Lin
  • Alessandro Bombonati
  • Benjamin J Stafford
  • Matthew E Witek
  • Inez Ruiz-Stewart
  • Juan P Palazzo
  • Jason Park
  • Dimas Yusuf
  • Jieru Egeria Lin
  • Vincenzo Ciocca
  • Matthias J Schnell
  • Gabriela Plesa
  • Xiaobing Tian
  • Ruth J Muschel
  • Weili Fu
  • Jay L Rothstein
  • Matthew Witek
  • Karl Nielsen
  • Juan Palazzo
  • Marcio A F de Godoy
  • Rhonda Walters
  • Satish R Tiyyagura
  • Sandeep Rathi
  • Kelly L Prince
  • Roland H Wenger
  • Gieri Camenisch
  • Bruce E Torbett
  • Miranda S C Wilson
  • Satrajit Sinha
  • Mark W Woodcroft
  • Capucine Van Rechem
  • Raquel Marco-Ferreres
  • Oliver Hankinson
  • Christopher J Harvey
  • Chunyan Zhao
  • Xin M Luo
  • Rachel D Mullen
  • Dominique Leprince
  • Sekhar P Reddy
  • Reiner A Veitia
  • David Laperriere
  • Juan Hou
  • Daniel J Peet
  • Gilbert Won Kim
  • Michael Anthony Valentino
  • Alison H Banham
  • Padma Sheela Jayaraman
  • Margaret R Hough
  • Michael Wegner
  • Ralf Kist
  • Leonardo L Beccari
  • Carol F Webb
  • Seth Frietze
  • Amy Ticoll
  • Stephanie C Colvin
  • Tiziana De Cristofaro
  • Angie Rizzino
  • Sylvie Mader
  • Harini Chakravarthy
  • Simon J Rhodes
  • Helma D C Schwenen
  • Warren A Cheung
  • Eugene Bolotin
  • Lara J Monteiro
  • Juliet M Daniel

Detail Information

Publications52

  1. pmc Molecular staging of node negative patients with colorectal cancer
    Terry Hyslop
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    J Cancer 4:193-9. 2013
    ..The diagnostic paradigm quantifying occult tumor burden using GUCY2C qRT-PCR is positioned to reduce racial disparities in colorectal cancer mortality...
  2. pmc GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity
    Jieru Egeria Lin
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 7:e31686. 2012
    ..The therapeutic potential of this observation is underscored by the emerging clinical development of oral GUCY2C ligands, which can be used for chemoprophylaxis in inflammatory bowel disease and cancer...
  3. doi Transitioning biomarkers into the clinic
    Scott A Waldman
    Thomas Jefferson University, 132 South 10th Street, Philadelphia, PA 19107, USA
    Expert Rev Clin Pharmacol 2:9-13. 2009
    b>Scott Waldman is currently the Chairman of the Department of Pharmacology and Experimental Therapeutics and the Director of the Division of Clinical Pharmacology...
  4. pmc The transcription factor encyclopedia
    Dimas Yusuf
    Department of Medical Genetics, Faculty of Medicine, Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, Canada
    Genome Biol 13:R24. 2012
    ..TFe aims to rapidly educate scientists about the TFs they encounter through the delivery of succinct summaries written and vetted by experts in the field. TFe is available at http://www.cisreg.ca/tfe...
  5. pmc Selection of optimal reference genes for normalization in quantitative RT-PCR
    Inna Chervoneva
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
    BMC Bioinformatics 11:253. 2010
    ..Current methods of selecting reference genes make an assumption of independence in their innate variation. This assumption is not always justified, which may lead to selecting a suboptimal set of reference genes...
  6. ncbi Clinical pharmacology: a paradigm for individualized medicine
    Scott A Waldman
    Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA
    Biomark Med 3:679-84. 2009
    ....
  7. doi MicroRNA signatures as diagnostic and therapeutic targets
    Scott A Waldman
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA
    Clin Chem 54:943-4. 2008
  8. pmc A study of microRNAs in silico and in vivo: diagnostic and therapeutic applications in cancer
    Scott A Waldman
    Department of Pharmacology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    FEBS J 276:2157-64. 2009
    ....
  9. pmc Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer
    Scott A Waldman
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 S 10th St, Philadelphia, PA 19107, USA
    JAMA 301:745-52. 2009
    ..Guanylyl cyclase 2C (GUCY2C) is a marker expressed by colorectal tumors that could reveal occult metastases in lymph nodes and better estimate recurrence risk...
  10. ncbi Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells
    Scott A Waldman
    Thomas Jefferson University, Jefferson Medical College, Department of Pharmacology and Experimental Therapeutics, Philadelphia, PA 19107, USA
    Future Oncol 2:705-16. 2006
    ....
  11. ncbi Relative quantification based on logistic models for individual polymerase chain reactions
    Inna Chervoneva
    Division of Biostatistics, Department of Clinical Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Stat Med 26:5596-611. 2007
    ..Real kinetic RT-PCR data are used to compare the proposed and standard methods. The methods are applied to the clinical data from the ongoing study of guanylyl cyclase C as a biomarker for colorectal cancer...
  12. ncbi Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction
    Inna Chervoneva
    Division of Biostatistics, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Anal Biochem 348:198-208. 2006
    ..These studies demonstrate that elimination of kinetic outliers from calibration standards and test samples improves the accuracy of absolute transcript quantification by RT-PCR...
  13. pmc Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9
    Wilhelm J Lubbe
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Cancer Res 69:3529-36. 2009
    ..The notion that GCC-mediated regulation of cancer cell MMP-9 disrupts metastasis, in turn, underscores the unexplored utility of GCC hormone replacement therapy in the chemoprevention of colorectal cancer progression...
  14. pmc GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients
    Alex Mejia
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Expert Rev Mol Diagn 9:777-85. 2009
    ....
  15. ncbi Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer
    Glen S Frick
    Respiratory and Inflammation Centre of Excellence for Drug Discovery, Discovery Medicine, GlaxoSmithKline, PA, USA
    Expert Rev Mol Diagn 5:701-13. 2005
    ....
  16. ncbi Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer
    Wilhelm J Lubbe
    Division of Clinical Pharmacology, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Clin Cancer Res 12:1876-82. 2006
    ..Conversely, whereas cancer cells within those tumors may induce stromal cells to produce MMP-9 and may be targets for MMP-9 activity, they are not the source of MMP-9 underlying metastasis...
  17. pmc STa peptide analogs for probing guanylyl cyclase C
    Xiaobing Tian
    Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Biopolymers 90:713-23. 2008
    ..Peptides 3 and 6 behaved as agonists in stimulating cGMP production. The results reveal that the toxic domain of STa can be reduced to 12 amino acids...
  18. ncbi Interruption of homologous desensitization in cyclic guanosine 3',5'-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins
    Giovanni M Pitari
    Division of Clinical Pharmacology, Department of Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Cancer Res 65:11129-35. 2005
    ..Thus, regimens that incorporate cytostatic bacterial enterotoxins and inhibitors of cGMP-mediated desensitization offer a previously unrecognized therapeutic paradigm for treatment and prevention of colorectal cancer...
  19. ncbi Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity
    Peng Li
    Department of Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Gastroenterology 133:599-607. 2007
    ..However, the role of GCC in neoplasia remains obscure...
  20. ncbi Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins
    Shiva Kazerounian
    Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    J Pharmacol Exp Ther 314:1013-22. 2005
    ..They suggest that combining guanylyl cyclase C agonists and SOC inhibitors offers a novel paradigm for cGMP-directed therapy and prevention for colorectal tumors...
  21. ncbi Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach
    Jason Park
    Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Cancer Epidemiol Biomarkers Prev 11:739-44. 2002
    ....
  22. ncbi A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer
    Stephanie Schulz
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 12:4545-52. 2006
    ..However, quantification of GCC expression in tissues by the quantitative reverse transcription-PCR (qRT-PCR) has not undergone analytic and clinicopathologic validation...
  23. ncbi Mucosally restricted antigens as novel immunological targets for antitumor therapy
    Adam E Snook
    Thomas Jefferson University, Department of Pharmacology and Experimental Therapeutics, Philadelphia, PA, USA
    Biomark Med 1:187-202. 2007
    ....
  24. pmc Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target
    Jieru E Lin
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA
    Future Oncol 5:509-22. 2009
    ..Compensatory upregulation of GCC in response to hormone loss provides a unique translational opportunity for prevention and treatment of colorectal tumors by hormone-replacement therapy...
  25. pmc Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis
    Peng Li
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA
    Cancer Biol Ther 10:211-8. 2010
    ....
  26. ncbi Soluble guanylate cyclase is allosterically inhibited by direct interaction with 2-substituted adenine nucleotides
    Inez Ruiz-Stewart
    Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Eur J Biochem 269:2186-93. 2002
    ..This allosteric inhibition is mediated by direct interaction of adenine nucleotides with sGC, likely at the catalytic domain in a region outside the substrate-binding site...
  27. doi Sex modulates intestinal transformation by the tumor-suppressor GCC
    Peng Li
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Transl Sci 1:146-50. 2008
    ..However, the molecular intersection between intestinal paracrine and systemic sex hormones opposing intestinal neoplasia has not been explored...
  28. pmc Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells
    Giovanni M Pitari
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1100 Walnut Street, MOB Suite 810, Philadelphia, PA 19107, USA
    Carcinogenesis 29:1601-7. 2008
    ..Restoration of antitumorigenic CaR signaling by GCC ligand replacement therapy represents a previously unrecognized paradigm for the prevention and treatment of human colorectal cancer employing dietary Ca(2+) supplementation...
  29. ncbi Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells
    Giovanni Mario Pitari
    Division of Clinical Pharmacology, Departments of Pharmacology and Experimental Therapeutics and Medicine, Thomas Jefferson University, 1100 Walnut Street MOB 810, Philadelphia, PA 19107, USA
    Mol Cancer Ther 5:1190-6. 2006
    ..Moreover, combination therapies, including exisulind and agents that induce cGMP signaling, may require careful evaluation in patients with colon cancer...
  30. ncbi Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer
    Paolo Fortina
    Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Jefferson Medical College, Philadelphia, PA 19107, USA
    Trends Biotechnol 25:145-52. 2007
    ..Although the scenarios outlined in this article are hypothetical, they might stimulate ideas about how other cancers could be attacked using nanotechnology...
  31. pmc Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity
    Adam E Snook
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 South Tenth St, Philadelphia, PA 19107, USA
    J Natl Cancer Inst 100:950-61. 2008
    ..Here we defined the immunogenicity and antitumor efficacy of guanylyl cyclase C (GCC), a protein that is normally restricted to intestinal mucosa and universally expressed by metastatic colorectal cancer...
  32. ncbi Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cells
    Philip R Debruyne
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Gastroenterology 130:1191-206. 2006
    ..The present studies examine the expression of GC-C in normal tissues and tumors from esophagus and stomach and mechanisms regulating its expression by acid and bile acids...
  33. ncbi The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas
    Matthew E Witek
    Division of Clinical Pharmacology, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Clin Cancer Res 11:8549-56. 2005
    ..Here, Cdx2 expression and function was quantified in tumors and matched normal mucosa from patients with colorectal cancer...
  34. ncbi Nitric oxide activation of soluble guanylyl cyclase reveals high and low affinity sites that mediate allosteric inhibition by calcium
    Shiva Kazerounian
    Division of Clinical Pharmacology, Department of Medicine and Biochemistry, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Biochemistry 41:3396-404. 2002
    ..These data suggest that sGC is a constitutive Ca(2+) binding protein whose allosteric function is conditionally dependent upon ligand activation...
  35. doi Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis
    Li Gong
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Transl Sci 2:286-93. 2009
    ..Induction of this axis provides the context for lineage-addicted tumorigenesis, in which autonomous activation of AKT corrupts adaptive intestinal NF-kappaB signaling, amplifying tumorigenic programs...
  36. pmc GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?
    P Li
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Drug News Perspect 22:313-8. 2009
    ..The correlative therapeutic hypothesis suggests that colorectal cancer is a disease of hormone insufficiency that can be prevented or treated by oral hormone replacement therapy employing GCC ligands...
  37. pmc Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms
    Vincenzo Ciocca
    Department of Pathology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA
    Histopathology 55:182-8. 2009
    ....
  38. ncbi Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract
    Ruth Birbe
    Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Hum Pathol 36:170-9. 2005
    ....
  39. pmc Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine
    Peng Li
    Division of Clinical Pharmacology, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1100 Walnut St MOB 810, Philadelphia, PA 19107, USA
    Am J Pathol 171:1847-58. 2007
    ..In the context of uniform loss of GC-C signaling during tumorigenesis, dysregulation of those homeostatic processes may contribute to mechanisms underlying colon cancer...
  40. ncbi Nitric oxide signaling: systems integration of oxygen balance in defense of cell integrity
    Li Gong
    Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Curr Opin Hematol 11:7-14. 2004
    ....
  41. pmc Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease
    Adam E Snook
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Cancer Res 69:3537-44. 2009
    ..These observations support the utility of GCC-targeted immunotherapy in patients at risk for systemic metastases, including those with inflammatory bowel disease, hereditary colorectal cancer syndromes, and sporadic colorectal cancer...
  42. ncbi Pathological staging and therapy of oesophageal and gastric cancer
    Philip R Debruyne
    Division of Clinical Pharmacology, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Expert Opin Pharmacother 4:1083-96. 2003
    ..Standard curative treatment for gastro-oesophageal junction and gastric cancer includes surgery and adjuvant chemoradiotherapy. Chemotherapy is an option for the treatment of advanced and recurrent gastric cancer...
  43. ncbi Functional and molecular characterization of beta-adrenoceptors in the internal anal sphincter
    Sandeep Rathi
    Department of Medicine, Division of Gastroenterology and Hepatology, Jefferson Medical College, Thomas Jefferson University, 1025 Walnut Street, Room no 901 College, Philadelphia, PA 19107, USA
    J Pharmacol Exp Ther 305:615-24. 2003
    ..These studies may have important implications in anorectal and other gastrointestinal motility disorders...
  44. ncbi H-ras inhibits RhoA/ROCK leading to a decrease in the basal tone in the internal anal sphincter
    Marcio A F de Godoy
    Departments of Medicine, Division of Gastroenterology and Hepatology, Pharmacology and Experimental Therapeutics, and Emergency Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennyslvania 19107, USA
    Gastroenterology 132:1401-9. 2007
    ..The present studies evaluated the role of H-ras and its implications in the RhoA/Rho kinase (ROCK) pathway in regulating basal tone in the internal anal sphincter (IAS)...
  45. ncbi Reciprocal regulation and integration of signaling by intracellular calcium and cyclic GMP
    Satish R Tiyyagura
    Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Vitam Horm 69:69-94. 2004
    ..This chapter describes the molecular mechanisms regulating intracellular Ca2+ and cGMP, and their integration in specific cellular responses...
  46. ncbi Derivation and fluidity of acutely induced dysfunctional CD8+ T cells
    Gabriela Plesa
    Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    J Immunol 180:5300-8. 2008
    ..Together, these results suggest that persistence of dysfunctional cells generated in this manner depends upon continual exposure to high Ag levels and that such cells may ultimately predominate if functional cells become exhausted...
  47. ncbi A comparative molecular field analysis (COMFA) of the structural determinants of heat-stable enterotoxins mediating activation of guanylyl cyclase C
    Henry R Wolfe
    Targeted Diagnostics and Therapeutics, Inc, 1045 Andrew Drive, West Chester, Pennsylvania 19380, USA
    J Med Chem 45:1731-4. 2002
    ....
  48. ncbi In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand
    Henry R Wolfe
    Research and Development Department, Targeted Diagnostics and Therapeutics, Inc, West Chester, Pennsylvania 19380, USA
    J Nucl Med 43:392-9. 2002
    ..This study examined the utility of a radiolabeled conjugate of STa (5--18) to selectively target and image extraintestinal human colon cancer xenografts in vivo in nude mice...
  49. ncbi Translating MicroRNA discovery into clinical biomarkers in cancer
    Scott A Waldman
    JAMA 297:1923-5. 2007
  50. ncbi Markers of cell cycle-mediated drug resistance and prognosis of patients receiving preoperative combined modality therapy for rectal cancer
    Scott A Waldman
    Ann Surg Oncol 11:949-50. 2004

Research Grants20

  1. Short-term Training Program in Translational Cancer Rese
    Scott Waldman; Fiscal Year: 2007
    ..abstract_text> ..
  2. CLINICAL PHARMACOLOGY TRAINING PROGRAM
    Scott Waldman; Fiscal Year: 2007
    ..Alternatively, fellows may opt for careers in the pharmaceutical industry or in regulatory clinical pharmacology. ..
  3. TRAINING PROGRAM IN HUMAN INVESTIGATION
    Scott Waldman; Fiscal Year: 2007
    ..Upon completion of the program, trainees are qualified to perform independent clinical research with certification through a Master's of Science in Human Investigation. ..
  4. GUANYLYL CYCLASE C IN BLOOD AND COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2006
    ..These studies will form the foundation for future trials utilizing GC-C to identify patients at risk for recurrence who might benefit from therapeutic intervention. ..
  5. GUANYLYL CYCLASE C IN BLOOD AND COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2007
    ..These studies will form the foundation for future trials utilizing GC-C to identify patients at risk for recurrence who might benefit from therapeutic intervention. ..
  6. GUANYLYL CYCLASE C IN BLOOD AND COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2007
    ..These studies will form the foundation for future trials utilizing GC-C to identify patients at risk for recurrence who might benefit from therapeutic intervention. ..
  7. GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2006
    ....
  8. GUANYLYL CYCLASE C IN BLOOD AND COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2005
    ..These studies will form the foundation for future trials utilizing GC-C to identify patients at risk for recurrence who might benefit from therapeutic intervention. ..
  9. GUANYLYL CYCLASE C AS A BIOMARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 1999
    ....
  10. GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2002
    ....
  11. GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2003
    ....
  12. GUANYLYL CYCLASE C IN BLOOD AND COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2003
    ..These studies will form the foundation for future trials utilizing GC-C to identify patients at risk for recurrence who might benefit from therapeutic intervention. ..
  13. GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2004
    ....
  14. GUANYLYL CYCLASE C IN BLOOD AND COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2004
    ..These studies will form the foundation for future trials utilizing GC-C to identify patients at risk for recurrence who might benefit from therapeutic intervention. ..
  15. TRAINING PROGRAM IN HUMAN INVESTIGATION
    Scott Waldman; Fiscal Year: 2004
    ..Upon completion of the program, trainees will be qualified to perform independent clinical research with certification through a Master's of Science in Human Investigation. ..
  16. GUANYLYL CYCLASE C AS A BI0MARKER FOR COLORECTAL CANCER
    Scott Waldman; Fiscal Year: 2005
    ....